Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

Last updated: October 30, 2023
Sponsor: Charite University, Berlin, Germany
Overall Status: Active - Recruiting

Phase

N/A

Condition

Uterine Disorders

Nasopharyngeal Cancer

Rectal Cancer

Treatment

Online adaptive radiation therapy

Clinical Study ID

NCT06116019
3000902
  • Ages > 18
  • All Genders

Study Summary

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients (>18 years)
  • All tumor entities with an indication for radiotherapy and/or chemoradiotherapy
  • Signed informed consent

Exclusion

Exclusion Criteria:

  • Pregnancy
  • Patients who are not capable of giving consent

Study Design

Total Participants: 649
Treatment Group(s): 1
Primary Treatment: Online adaptive radiation therapy
Phase:
Study Start date:
October 11, 2023
Estimated Completion Date:
October 09, 2027

Connect with a study center

  • Charité - Universitätsmedizin

    Berlin,
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.